Virion is a clinical stage company developing novel T cell-based immunotherapies for cancer and infectious diseases. What makes Virion unique is their proprietary technology, known as checkpoint modifiers, which alters T cell activation to enhance and broaden responses to include regions of cancers and infectious diseases that are not normally stimulated during a chronic disease. This disruptive, first in class immune modulators, “removes the brakes AND hits the gas” on the immune system. Virion’s Lead Clinical Program, VRON-0200, which has sites in the APAC region (Hong Kong and New Zealand), recently presented data at a Global European Liver Meeting, EASL, and a Global Asian Liver Meeting in Beijing, that many experts have commented have a high potential to change the HBV functional cure landscape with VRON-0200 as the backbone treatment for functional cure.